Soheir Adam

Soheir Adam

Auto-generated profile, based on publicly available information

Soheir Adam

Duke University, Division of Hematology, Department of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
SASoheir S. Adam
Soheir S. Adam
CFCharlene M. Flahiff
Charlene M. Flahiff
SKShital Kamble
Shital Kamble
MTMarilyn J. Telen
Marilyn J. Telen
SRShelby D. Reed
Shelby D. Reed
LCLaura M. De Castro
Laura M. De Castro
Key Points: Depression was found in 35.2% of adult SCD patients and was strongly associated with worse physical and mental quality-of-life outcomes. Total health care costs for adult SCD patients with depression were more than double those of SCD patients without depression.

20 August 2013 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SASoheir S. Adam
Soheir S. Adam
JMJennifer R. McDuffie
Jennifer R. McDuffie
PLPaul F. Lachiewicz
Paul F. Lachiewicz
TOThomas L. Ortel
Thomas L. Ortel
JWJohn W. Williams
John W. Williams
Pharmacologic thromboprophylaxis reduces the risk for venous thromboembolism after total hip replacement (THR) or total knee replacement (TKR). New oral anticoagulants (NOACs), including direct thrombin inhibitors and factor Xa inhibitors, are emerging options for thromboprophylaxis after these procedures. To compare the benefits and risks of NOACs versus standard thromboprophylaxis for adults having THR or TKR. MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from January 2009 through March 2013. English-language systematic reviews. Two independent reviewers abstracted data and rated study quality and strength of evidence. Six good-quality systematic reviews compared NOACs with low-molecular-weight heparin (LMWH) for thromboprophylaxis after THR or TKR. Risk for symptomatic deep venous thrombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events per 1000 patients). Conversely, the risk for major bleeding increased (2 more events per 1000 patients). Outcomes of dabigatran did not significantly differ from those of LMWH. Indirect evaluation of NOACs by common comparison with LMWH showed nonsignificantly reduced risks for venous thromboembolism with rivaroxaban compared with dabigatran (risk ratio [RR], 0.68 [95% CI, 0.21 to 2.23]) and apixaban (RR, 0.59 [CI, 0.26 to 1.33]) but increased major bleeding. New oral anticoagulants have not been compared with warfarin, aspirin, or unfractionated heparin. Head-to-head comparisons among NOACs were not available. Efficacy is uncertain in routine clinical practice. New oral anticoagulants are effective for thromboprophylaxis after THR and TKR. Their clinical benefits over LMWH are marginal and offset by increased risk for major bleeding. U.S. Department of Veterans Affairs.

1 October 2008 in The American Journal of Medicine
Verified
Journal Article
Closed access
SASoheir Adam
Soheir Adam
JJJude Jonassaint
Jude Jonassaint
HKHillary Kruger
Hillary Kruger
MKMelanie Kail
Melanie Kail
EOEugene P. Orringer
Eugene P. Orringer
LCLaura M. De Castro
Laura M. De Castro

2 January 2017 in Hemoglobin
Verified
Journal Article
Closed access
SASoheir Adam
Soheir Adam
HAHanan Afifi
Hanan Afifi
MTManal Thomas
Manal Thomas
PMPhoebe Magdy
Phoebe Magdy
GEGhada El-Kamah
Ghada El-Kamah
Thalassemia is a disorder of hemoglobin (Hb) synthesis characterized by chronic hemolysis. In β-thalassemias major (β-TM), patients require regular transfusion at an early age due to severe anemia. Subsequently, intensive chelation therapy is initiated to mitigate the effects of the resultant iron overload. Clinical disease burden and the demanding treatment can affect health-related quality of life (HRQoL) outcomes in this population. The aim of this study was to assess HRQoL outcomes in Egyptian pediatric thalassemia patients. Patients were enrolled simultaneously from the hematology clinic at the National Research Institute in Cairo, Egypt. The Arabic version of SF36 tool was used to assess HRQoL outcomes. Socioeconomic data were collected by patient and parent interviews. Clinical data were collected by review of medical records. One hundred and thirty patients and 60 controls were enrolled, with a mean age of 5.4 ± 3.2 years and 6.3 ± 3.0, respectively. The HRQoL outcome scores were lower in all domains in the thalassemia group compared to the control group (p = 0.0001). Transfusion-dependent (TD) patients had lower HRQoL scores compared to nontransfusion-dependent (NTD) patients (p = 0.0001). Patient education and maternal education were independently associated with better HRQoL scores (p = 0.007, p = 0.028, respectively). Residents of rural areas reported lower scores compared to urban residents (p = 0.026). Thalassemia was associated with lower HRQoL scores, in all domains, compared to HRQoL in unaffected controls. Chronic transfusion independence, patient education, and maternal education were all associated with higher HRQoL scores. Psychological, social, and economic support for families with thalassemia are all essential tools to improve HRQoL outcomes.

1 March 2021 in Thrombosis Research
Verified
Journal Article
Closed access
THTarek Haykal
Tarek Haykal
SASoheir Adam
Soheir Adam
ABAreeg Bala
Areeg Bala
YZYazan Zayed
Yazan Zayed
SDSmit Deliwala
Smit Deliwala
TOThomas L. Ortel
Thomas L. Ortel

1 October 2020 in Thrombosis Research
Verified
Journal Article
Closed access
THTarek Haykal
Tarek Haykal
YZYazan Zayed
Yazan Zayed
SDSmit Deliwala
Smit Deliwala
JKJosiane Kerbage
Josiane Kerbage
APAnoosha Ponnapalli
Anoosha Ponnapalli
SASoheir Adam
Soheir Adam